Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter.
Cyclacel Pharmaceuticals Stock Performance
Shares of NASDAQ:CYCC opened at $0.30 on Monday. The stock has a market capitalization of $1.87 million, a price-to-earnings ratio of -0.03 and a beta of 0.28. Cyclacel Pharmaceuticals has a 1-year low of $0.29 and a 1-year high of $4.00. The company has a 50 day moving average price of $0.35 and a 200 day moving average price of $0.57.
Insider Activity at Cyclacel Pharmaceuticals
In other Cyclacel Pharmaceuticals news, CEO David E. Lazar sold 194,628,820 shares of the stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $0.03, for a total value of $5,838,864.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 23.97% of the stock is owned by insiders.
Wall Street Analyst Weigh In
View Our Latest Stock Analysis on CYCC
Cyclacel Pharmaceuticals Company Profile
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.
Featured Stories
- Five stocks we like better than Cyclacel Pharmaceuticals
- What Does a Stock Split Mean?
- How to Build the Ultimate Everything ETF Portfolio
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- 5 discounted opportunities for dividend growth investors
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.